Focused Versus Multi-Target Trigger Point Injection for Chronic Myofascial Neck Pain

NCT ID
NCT07876739
Registry status
Not yet recruiting
Study type
Interventional
Phase
Not applicable
Sponsor
Mardin Artuklu University
Conditions
Chronic Neck Pain, Myofacial Pain Syndrome

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: Focused Versus Multi-Target Trigger Point Injection in Chronic Myofascial Neck Pain: A Participant- and Assessor-Blinded Randomized Controlled Trial

Enrollment: 100 participants (Estimated).

What is being studied

  • Intervention: Acetanilides
  • Intervention: Amides
  • Intervention: Amines
  • Intervention: Anilides
  • Intervention: Aniline Compounds
  • Intervention: Lidocaine
  • Drug: Lidocaine 1% Trigger Point Injection
  • Intervention: Organic Chemicals

Who may be eligible

Ages
18 Years to 65 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Age 18 to 65 years * Chronic myofascial neck or cervicoscapular pain for at least 3 months * Average pain intensity during the previous 7 days of at least 4/10 on the Numeric Rating Scale * Presence of active myofascial trigger points in at least two different muscles among the upper trapezius, levator scapulae, and infraspinatus muscles * Willingness to participate in the study and provide written informed consent Exclusion Criteria: * Cervical radiculopathy or myelopathy * Fibromyalgia * Neurological, rheumatological, or structural disease that may explain the neck or cervicoscapular pain * History of major surgery involving the neck or shoulder girdle, or trauma that may significantly affect clinical assessment * Trigger point injection or dry needling in the cervicoscapular region within the previous 3 months * Active infection, open wound, or significant skin lesion at the injection site * Active systemic infection * Known allergy to lidocaine or other amide-type local anesthetics * Known bleeding disorder, clinically significant thrombocytopenia, or anticoagulant treatment associated with an unacceptable bleeding risk for injection * Pregnancy * Severe cognitive or communication impairment that would prevent reliable completion of study assessments * Inability or unwillingness to provide written informed consent

Study locations

1 study location is listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: Turkey (Türkiye)

Sample of listed locations

  • Mardin Training and Research Hospital — Mardin, 47100, Turkey (Türkiye) — Site recruitment status not specified in the registry data

Study details

Start date
April 1, 2027
Primary completion date
January 15, 2028
Completion date
February 20, 2028
First posted
October 15, 2026
Collaborators
Mardin Training and Research Hospital

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07876739
Registry last updated
October 15, 2026
QualifiedStudies registry data refreshed
October 19, 2026
QualifiedStudies record fetched
October 19, 2026

View NCT07876739 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Neck Pain studies | Clinical trial FAQ